JPMorgan analyst Jessica Fye reiterated an Overweight rating and $36.00 price target on Insmed (NASDAQ: INSM)The analyst comments "This morning ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE